The Killer-Acquisition Myth: What the Data Actually Shows

September 21, 2026 · AcquisitionsTalent retentionInnovation

There’s a durable story in business about “killer acquisitions”: a big company buys a promising startup, folds it in, and the innovation that made the startup interesting quietly dies inside the acquirer’s bureaucracy. It’s a believable story. It’s also more complicated than the headlines suggest.

The phrase comes from a influential 2021 Journal of Political Economy paper by Colleen Cunningham, Florian Ederer, and Song Ma. They examined the pharmaceutical industry and found that 5.3–7.4% of drug-company acquisitions were “killer acquisitions” — deals where the buyer acquired a target specifically to discontinue a competing drug project. For projects whose pipeline overlapped with the acquirer’s existing portfolio, the probability of the drug ever being developed dropped by 23.4%. These acquisitions disproportionately clustered just below the price thresholds that would trigger antitrust scrutiny.

The finding was widely reported. It also answers a different question than the one people usually ask about it.

Pharma kills products. Tech acquires people.

The killer-acquisition paper studied the pharmaceutical industry. The unit of analysis was drug projects — a target company’s intellectual property pipeline, not the people who designed the drugs. When a big pharma company acquires a small biotech, it often closes the target’s R&D pipeline if those projects overlap with its own. That’s a product decision.

But most of the “killer acquisition” fear in recent years is about something different: what happens to the people when a tech company acquires a startup. This is the “acqui-hire” — an acquisition where the primary asset is the team, not the product or IP. The team is hired on, the company is dissolved or reduced to a shell, and the acquisition is judged entirely on whether those people stay and become productive inside the acquirer.

These are fundamentally different outcomes. The killer-acquisition paper tells us about what happens to products when they’re absorbed. It says nothing about what happens to people.

What happens to people after an acqui-hire

That’s where different research speaks to us. A recent study by Nikolaus Seitz and Erik Lehmann (2025) examined 241 acquisitions by Google and Meta involving acqui-hired founders — 454 individuals across those deals. Their findings challenge the killer-acquisition narrative, but in a very specific way.

Serial entrepreneurs are almost twice as likely as first-time founders to leave the acquirer within the first three years. An entrepreneur who has already built and exited a company understands the corporate environment. They may treat an acqui-hire as a stepping stone, not a destination.

Teams that stay together stay longer. When entire co-founder teams are acqui-hired as a unit, retention is significantly higher than when founders leave their co-founders behind. But it’s not just about preserving the headcount — it’s about preserving the hierarchy. When the acquirer redistributes status so that one founder outranks another, turnover spikes.

High-status roles and intact tech help — up to a point. Giving the founder a meaningful role, with real decision-making power, and keeping the acquired startup’s technology in the acquirer’s portfolio reduces premature departure. But these measures are effective primarily in the first three years, after which their impact diminishes sharply. The structure of large organizations ultimately resists sustaining entrepreneurial autonomy.

A separate 2023 study in the Strategic Management Journal arrived at a similar conclusion. The key variable was the type of know-how the acquired startup possessed. When the know-how was “disruptive” to the acquirer’s existing business, the acquirer was more likely to preserve the team as a whole and assign the founder a high-status position. When the know-how was complementary rather than disruptive, the team was more likely to be dispersed across the acquirer’s existing org structure.

The data does converge

What these studies together reveal is a simple but poorly understood truth:

What management can actually do

The research gives us actionable guidance, not just narrative. If you’re managing an acqui-hire — on either side of the deal — here’s what the evidence says matters:

Preserve the team’s internal structure. Don’t redistribute seniority among co-founders. The data is clear: hierarchical disruption is a leading driver of early departure.

Give the founder real status. Not a title. A role with decision-making authority over technology and direction. The studies link this directly to extended retention.

Plan for the three-year cliff. Integration plays that work for the first 18–24 months lose their effect by year three. If the goal is long-term value, you need structural commitments, not just promises.

Expect the attrition. 33% is the number. Any acqui-hire plan that assumes more than two-thirds of the team will remain after a year is gambling with the wrong odds.

What this doesn’t tell you

These studies are about tech acqui-hires. They don’t speak to traditional M&A, to private-equity roll-ups, to cross-border consolidation, or to the new “reverse acqui-hire” deal structures where companies now pay licensing fees to pluck founding teams off startups without technically acquiring the company at all. They also don’t measure the impact on the acquirer’s existing employees, who may lose opportunities, autonomy, or morale when an acquired team is given privileged status.

But they do give us something that the “killer acquisition” narrative lacks: evidence about what actually happens after the deal closes, not just what the deal was designed to achieve.

Sources:

← All Articles